Key Melanoma Treatment Updates, focusing on Immunotherapy vs. Targeted Therapy Sequencing скачать в хорошем качестве

Key Melanoma Treatment Updates, focusing on Immunotherapy vs. Targeted Therapy Sequencing

Dr. Gino K. In, MD, MPH, Associate Professor of Medicine at USC Norris Comprehensive Cancer Center, for an exclusive interview at MOASC Spotlight in Newport Beach, CA. He shares key melanoma treatment updates, focusing on immunotherapy vs. targeted therapy sequencing for BRAF V600-mutant melanoma (DREAMSeq trial), long-term benefits of Lifileucel (TIL therapy) for advanced cases after failure, and adjuvant PD-1 therapy to prevent recurrence in high-risk cutaneous squamous cell carcinoma (C-POST study). Discover why immunotherapy is preferred for better survival, how up to 1/3 of refractory patients respond to Lifileucel, and the dramatic DFS benefit (HR 0.31) from adjuvant PD-1. Perfect for oncologists, patients, and researchers seeking actionable insights on skin cancer therapies. Notable quotes: "So we really think that when it comes to survival, using immunotherapy first is the preferred option." "Even patients who've had almost every other available melanoma therapy and not respond to those therapies, up to a third of those will respond to TIL therapy or Lifileucel." "There was a clear benefit with a hazard ratio of 0.31, clearly favoring the role of adjuvant PD-1."